Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · see citing works

Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study

Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · see citing works

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711 · see citing works

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,602 · see citing works

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H. P., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Ngai, J., Holmgren, E. B., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 934 · see citing works

Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W. J., Berlin, J. D., Holmgren, E. B., Hambleton, J., Novotny, W. F., & Kabbinavar, F. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 687 · see citing works

Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases

Adam, R. A., Avisar, E., Ariche, A., Giachetti, S., Azoulay, D., Castaing, D., Kunstlinger, F., Lévi, F., & Bismuth, F. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0347-3 · Cited by 656 · see citing works

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J. L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 629 · see citing works

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Schneider, B. P., Wang, Μ., Radovich, M., Sledge, G. W., Badve, S., Thor, A. D., Flockhart, D. A., Hancock, B. A., Davidson, N. E., Gralow, J. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604 · see citing works

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Cutsem, E. V., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H., Allegra, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2090 · Cited by 252 · see citing works

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials

Kabbinavar, F. F., Hurwitz, H. I., Yi, J., Sarkar, S., & Rosen, O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7931 · Cited by 180 · see citing works

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

Johnson, K. R., Ringland, C. L., Stokes, B., Anthony, D., Freemantle, N., Irs, A., Hill, S. R., & Ward, R. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70800-2 · Cited by 176 · see citing works

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

Ross, P. J., Norman, A. R., Cunningham, D., Webb, A., Iveson, T. J., Padhani, A. R., Prendiville, J., Watson, M., Massey, A., Popescu, R. A., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008263516099 · Cited by 128 · see citing works

Anti-angiogenic therapies for metastatic colorectal cancer

Wagner, D., Arnold, D., Grothey, A. A., Haerting, J., & Unverzagt, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005392.pub3 · Cited by 119 · see citing works

16LBA VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer

Lambrechts, D., Delmar, P., Buysschaert, I., Claes, B., Yesilyurt, B. T., Verslype, C., Foernzler, D., Carmeliet, P., Scherer, S., & Cutsem, E. V. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72051-8 · Cited by 13 · see citing works

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · see citing works

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467 · see citing works

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

Hashiguchi, Y., Muro, K., Saitō, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,936 · see citing works

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · see citing works

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · see citing works

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,509 · see citing works

Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial

Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · see citing works

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167 · see citing works

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Franko, J., Shi, Q., Meyers, J. P., Maughan, T., Adams, R., Seymour, M., Saltz, L. B., Punt, C. J. A., Koopman, M., Tournigand, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30500-9 · Cited by 688 · see citing works

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

Cunningham, D., Láng, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D. J., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 641 · see citing works

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0801-z · Cited by 591 · see citing works

Metastatic Colorectal Cancer: Current State and Future Directions

Fakih, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7633 · Cited by 529 · see citing works

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Simkens, L. H. J., van Tinteren, H., May, A. M., ten Tije, A. J., Creemers, G., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 522 · see citing works

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

Papamichael, D., Audisio, R. A., Glimelius, B. L. G., de Gramont, A., Glynne‐Jones, R., Haller, D. G., Köhne, C. H., Rostoft, S., Lemmens, V. E. P. P., Mitry, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu253 · Cited by 475 · see citing works

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial

Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00042-x · Cited by 251 · see citing works

Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis

Abdel-Qadir, H. M., Ethier, J.-L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.002 · Cited by 256 · see citing works

Anti-VEGF therapies in the clinic

Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237 · see citing works

S3-Leitlinie – Kolorektales Karzinom

Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 242 · see citing works

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials

Hurwitz, H. I., Tebbutt, N. C., Kabbinavar, F. F., Giantonio, B. J., Guan, Z.-Z., Mitchell, L., Waterkamp, D., & Tabernero, J. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0107 · Cited by 237 · see citing works

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

CSCO colorectal cancer working group (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.01.07 · Cited by 233 · see citing works

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Peeters, M., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., Punt, C. J. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt523 · Cited by 215 · see citing works

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A. J., Townsend, A. R., Wrin, J., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 210 · see citing works

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients

Totzeck, M., Mincu, R. I., & Rassaf, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006278 · Cited by 193 · see citing works

Colorectal carcinogenesis-update and perspectives

Raskov, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18151 · Cited by 182 · see citing works

Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications

Guo, X. W., Yi, H. L., Li, T. C., Wang, Y., Wang, H., & Chen, X. (2021) · Biomolecules · doi:10.3390/biom11020253 · Cited by 180 · see citing works

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 175 · see citing works

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

Rosen, L. S., Jacobs, I. A., & Burkes, R. L. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0518-1 · Cited by 167 · see citing works

Cancer Immunotherapy

Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 156 · see citing works

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Passardi, A., Nanni, O., Tassinari, D., Turci, D., Cavanna, L., Fontana, A., Ruscelli, S., Mucciarini, C., Lorusso, V., Ragazzini, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv130 · Cited by 158 · see citing works

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Kwakman, J. J. M., Elshot, Y. S., Punt, C. J. A., & Koopman, M. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.442 · Cited by 155 · see citing works

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Kerr, R. S., Love, S., Segelov, E., Johnstone, E. C., Falcón, B. L., Hewett, P. J., Weaver, A., Church, D. N., Scudder, C. L., Pearson, S. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30172-3 · Cited by 152 · see citing works

Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy

Sápi, J., Kovács, L., Drexler, D. A., Kocsis, P., Gajári, D., & Sápi, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142190 · Cited by 147 · see citing works

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Mooi, J. K., Wirapati, P., Asher, R., Lee, C. K., Savas, P. S., Price, T. J., Townsend, A. R., Hardingham, J. E., Buchanan, D. D., Williams, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy410 · Cited by 144 · see citing works

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Koeberle, D., Betticher, D. C., von Moos, R., Dietrich, D., Brauchli, P., Baertschi, D., Matter-Walstra, K. W., Winterhalder, R., Borner, M., Anchisi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv011 · Cited by 141 · see citing works

Management of colorectal cancer

Stintzing, S. (2014) · F1000Prime Reports · doi:10.12703/p6-108 · Cited by 142 · see citing works

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Sjoquist, K. M., Renfro, L. A., Simes, R. J., Tebbutt, N. C., Clarke, S. J., Seymour, M., Adams, R., Maughan, T., Saltz, L. B., Goldberg, R. M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx253 · Cited by 130 · see citing works

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

Macedo, L. T., Lima, A. B. C., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 126 · see citing works

Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review

Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 126 · see citing works

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00216-8 · Cited by 123 · see citing works

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C

Price, T. J., Zannino, D., Wilson, K., Simes, R. J., Cassidy, J., Hazel, G. A. V., Robinson, B. A., Broad, A., Ganju, V., Ackland, S. P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr488 · Cited by 123 · see citing works

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis

Botrel, T. E. A., Clark, L. G. D. O., Paladini, L. M., & Clark, O. A. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2734-y · Cited by 125 · see citing works

Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action

Heinemann, V., Douillard, J., Ducreux, M. P., & Peeters, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.011 · Cited by 118 · see citing works

Hypoxia signaling in cancer: Implications for therapeutic interventions

Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works

ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers

Aisner, D. L., Nguyen, T. T., Paskulin, D. D., Le, A. T., Haney, J., Schulte, N., Chionh, F. J. M., Hardingham, J. E., Mariadason, J. M., Tebbutt, N. C., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0479-t · Cited by 116 · see citing works

Targeting synovial neoangiogenesis in rheumatoid arthritis

Leblond, A., Allanore, Y., & Avouac, J. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.005 · Cited by 115 · see citing works

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside

Arjaans, M., Schroder, C. P., Oosting, S. F., Dafni, U. G., Kleibeuker, J. E., & de Vries, E. G. E. (2016) · Oncotarget · doi:10.18632/oncotarget.6918 · Cited by 113 · see citing works

Role of bevacizumab in colorectal cancer growth and its adverse effects: A review

Pavlidis, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i31.5051 · Cited by 106 · see citing works

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Tabernero, J. M., Hozak, R. R., Yoshino, T., Cohn, A. L., Obermannova, R. L., Bodoky, G., García‐Carbonero, R., Ciuleanu, T., Portnoy, D. C., Prausová, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx767 · Cited by 106 · see citing works

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt231 · Cited by 104 · see citing works

Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data

Kirstein, M. M., Lange, A., Prenzler, A., Manns, M. P., Kubicka, S., & Vogel, A. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0032 · Cited by 104 · see citing works

Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis

Cao, Z., Shang, B., Zhang, G., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.08.001 · Cited by 103 · see citing works

Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database

Shi, Q., de Gramont, A., Grothey, A., Zalcberg, J. R., Chibaudel, B., Schmoll, H., Seymour, M., Adams, R., Saltz, L. B., Goldberg, R. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5887 · Cited by 100 · see citing works

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials

Roviello, G., Bachelot, T., Hudis, C. A., Curigliano, G., Reynolds, A. R., Petrioli, R., & Generali, D. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.026 · Cited by 95 · see citing works

Therapeutic strategy in unresectable metastatic colorectal cancer

Chibaudel, B., Tournigand, C., André, T., & de Gramont, A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011431592 · Cited by 93 · see citing works

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Strickler, J. H., & Hurwitz, H. I. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0003 · Cited by 85 · see citing works

The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review

Amit, L., Ben‐Aharon, I., Vidal, L., Leibovici, L., & Stemmer, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051780 · Cited by 83 · see citing works

Value of bevacizumab in treatment of colorectal cancer: A meta-analysis

Qu, C.-Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i16.5072 · Cited by 82 · see citing works

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

Wang, F., Chen, G., Zhang, Z., Yuan, Y., Wang, Y., Gao, Y., Sheng, W., Wang, Z., Li, X., Yuan, X., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12639 · Cited by 86 · see citing works

Systemic treatment for metastatic colorectal cancer in the era of precision medicine

Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 80 · see citing works

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

Kinugasa, Y., Uehara, K., Yamaguchi, K., Saito, Y., Murofushi, K. N., Sugai, T., Ishiguro, M., Ishihara, S., Ueno, H., Oka, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02899-8 · Cited by 90 · see citing works

Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice

Peeters, M., & Price, T. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.08.002 · Cited by 79 · see citing works

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group

Kwakman, J. J. M., Simkens, L. H. J., van Rooijen, J. M., van de Wouw, A. J., ten Tije, A. J., Creemers, G. J. M., Hendriks, M. P., Los, M., van Alphen, R. J., Polée, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx122 · Cited by 79 · see citing works

Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review

Chibaudel, B., Tournigand, C., Bonnetain, F., Richa, H., Benetkiewicz, M., André, T., & de Gramont, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015572343 · Cited by 75 · see citing works

Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis

Baraniskin, A., Buchberger, B., Pox, C. P., Graeven, U., Holch, J. W., Schmiegel, W., & Heinemann, V. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.009 · Cited by 75 · see citing works

Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections

Levin, A. M., Rusu, I., Orlin, A., Patel, M. M., Coombs, P. G., D’Amico, D. J., & Kiss, S. (2017) · Clinical ophthalmology · doi:10.2147/opth.s118807 · Cited by 73 · see citing works

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 78 · see citing works

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

Giessen, C. A., Laubender, R. P., Ankerst, D. P., Stintzing, S., Modest, D. P., Mansmann, U., & Heinemann, V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1515 · Cited by 68 · see citing works

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin

Láng, I., Köhne, C.-H., Folprecht, G., Rougier, P. R., Curran, D., Hitre, E., Sartorius, U., Griebsch, I., & Cutsem, E. V. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.023 · Cited by 71 · see citing works

Therapeutic Targeting of the Colorectal Tumor Stroma

Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 69 · see citing works

Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer

Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez‐Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 70 · see citing works

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer

Petrelli, F., & Barni, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds289 · Cited by 68 · see citing works

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease

Aparicio, J., Esposito, F. M., Serrano, S., Falcó, E., Escudero, P., Ruiz‐Casado, A., Manzano, H., & Montés, A. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123889 · Cited by 70 · see citing works

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

Weickhardt, A. J., Williams, D. S., Lee, C. K., Chionh, F. J. M., Simes, J. R., Murone, C., Wilson, K., Parry, M. M., Asadi, K., Scott, A. M., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.209 · Cited by 66 · see citing works

Biomarkers for Anti-Angiogenic Therapy in Cancer

Wehland, M., Bauer, J. W., Magnusson, N. E., Infanger, M., & Grimm, D. G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059338 · Cited by 64 · see citing works

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Cutsem, E. V., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne‐Jones, R., Punt, C. J. A., van de Wouw, A. J., Fedyanin, M. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.024 · Cited by 60 · see citing works

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

Bennett, L., Zhao, Z., Barber, B. R., Zhou, X., Peeters, M., Zhang, J., Xu, F., Wiezorek, J. S., & Douillard, J.-Y. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.409 · Cited by 59 · see citing works

Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis

Zhao, T., Wang, X., Xu, T., Xu, X., & Liu, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.18190 · Cited by 60 · see citing works

Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients.

Xu, H., Huang, X., Zhi-ying, Q., Xu, X., Li, Y., & Li, C.-G. (2011) · PubMed · Cited by 58 · see citing works

Vessel pruning or healing: endothelial metabolism as a novel target?

Cantelmo, A. R., Pircher, A., Kalucka, J. M., & Carmeliet, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1282465 · Cited by 58 · see citing works

Oral versus intravenous fluoropyrimidines for colorectal cancer

Chionh, F. J. M., Lau, D., Yeung, Y. H., Price, T. J., & Tebbutt, N. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008398.pub2 · Cited by 56 · see citing works

Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach – present status

Glimelius, B. L. G., & Cavalli‐Björkman, N. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640828 · Cited by 57 · see citing works

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Cremolini, C., Loupakis, F., Masi, G., Lonardi, S., Granetto, C., Mancini, M. L., Chiara, S., Moretto, R., Rossini, D., Vitello, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw052 · Cited by 56 · see citing works

Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups

Qi, W., Shen, Z., Tang, L., & Yao, Y. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1687-9 · Cited by 54 · see citing works

Targeted therapy for metastatic colorectal cancer

Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54 · see citing works

The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer

Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 52 · see citing works

Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis

Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, A. G., Rouleau, T., Cooksley, C. D., Halm, J. K., Vithala, M. V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1821-8 · Cited by 52 · see citing works

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

Feliú, J., Safont, M. J., Salud, A., Losa, F., Girón, C. G., Bosch, C., Escudero, P., López, R., Madroñal, C., Bolaños, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605663 · Cited by 51 · see citing works

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)

Modest, D. P., von Weikersthal, L. F., Decker, T. W., Vehling‐Kaiser, U., Uhlig, J., Schenk, M., Freiberg‐Richter, J., Peuser, B., Denzlinger, C., Reddemann, C. P. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00052 · Cited by 50 · see citing works

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients

Hsu, H., Lapke, N., Chen, S., Lu, Y., Jhou, R., Yeh, C.-Y., Tsai, W., Hung, H., Hsieh, C., Yang, T., et al. (2018) · Cancers · doi:10.3390/cancers10090314 · Cited by 50 · see citing works

Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.

Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005724 · Cited by 46 · see citing works

Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis

Galfrascoli, E., Piva, S., Cinquini, M., Rossi, A., Verde, N. M. L., Bramati, A., Moretti, A., Manazza, A. D., Damia, G. L. M., Torri, V., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.010 · Cited by 48 · see citing works

Haematologic toxicities associated with the addition of bevacizumab in cancer patients

Schutz, F. A. B., Jardim, D. L. F., Je, Y., & Choueiri, T. K. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.005 · Cited by 49 · see citing works

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Bonnetain, F., Borg, C., Adams, R., Ajani, J. A., Benson, A. B., Bleiberg, H., Chibaudel, B., Díaz‐Rubio, E., Douillard, J., Fuchs, C. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx191 · Cited by 49 · see citing works

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial

Santhosh, A. P., Sharma, A., Bakhshi, S., Kumar, A., Sharma, A., Malik, P. S., Pramanik, R., Gogia, A., Prasad, C. P., Sehgal, T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01730 · Cited by 48 · see citing works

A population‐based study of metastatic colorectal cancer in individuals aged ≥80 years

Kumar, R., Jain, K., Beeke, C., Price, T. J., Townsend, A. R., Padbury, R., Roder, D. M., Young, G. P., Richards, A. M., & Karapetis, C. S. (2012) · Cancer · doi:10.1002/cncr.27802 · Cited by 47 · see citing works

Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review

Schuurhuizen, C. S. E. W., Braamse, A. M. J., Konings, I. R. H. M., Sprangers, M. A. G., Ket, J. C. F., Dekker, J., & Verheul, H. M. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw617 · Cited by 46 · see citing works

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab

Tebbutt, N. C., Murphy, F., Zannino, D., Wilson, K., Cummins, M. M., Abdi, E. A., Strickland, A. H., Lowenthal, R. M., Marx, G. M., Karapetis, C. S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq702 · Cited by 45 · see citing works

A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial

Glockzin, G., Rochon, J., Arnold, D., Lang, S. A., Klebl, F. H., Zeman, F., Koller, M. T., Schlitt, H. J., & Piso, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-67 · Cited by 45 · see citing works

Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial

Zhao, H., Wang, Y., Yu, J., Wei, F., Cao, S., Zhang, X., Dong, N., Li, H. Y., & Ren, X. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.02.005 · Cited by 44 · see citing works

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43 · see citing works

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S. J., Díaz‐Rubio, E., Scheithauer, W., Figer, A., Wong, R. P. W., Koski, S. L., Lichinitser, M., Yang, T., Rivera, F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02760 · Cited by 239 · see citing works

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Schmiegel, W., Reinacher-Schick, A. C., Arnold, D., Kubicka, S., Freier, W., Dietrich, G., Geißler, M., Hegewisch-Becker, S., Tannapfel, A., Pohl, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt028 · Cited by 68 · see citing works

International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial

Tebbutt, N. C., Gebski, V., Wilson, K., Cummins, M. M., Chua, Y. J., Robinson, B. A., Broad, A., Cunningham, D., Simes, J. R., & Price, T. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4023 · Cited by 11 · see citing works

A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Hong, Y. S., Lee, S. S., Kim, K., Lee, J., Kang, Y., Shin, S. J., Ahn, J. B., Jung, K. H., Im, S., Kim, T., et al. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31826b9c94 · Cited by 9 · see citing works

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials

Chen, Y.-X., Yang, Q., Kuang, J., Chen, S.-Y., Wei, Y., Jiang, Z.-M., & Xie, D.-R. (2014) · Gastroenterology Research and Practice · doi:10.1155/2014/594930 · Cited by 21 · see citing works